Exploring the role of the inflammasomes on prostate cancer: Interplay with obesity
Authors:
- Jesús M. Pérez-GómezJPJesús M. Pérez-Gómez
- Antonio J. Montero-HidalgoAMAntonio J. Montero-Hidalgo
- Antonio C. Fuentes-FayosAntonio C. Fuentes-Fayos
- André Sarmento-CabralASAndré Sarmento-Cabral
- Rocio Guzmán-RuizRGRocio Guzmán-Ruiz
- María M. MalagónMMMaría M. Malagón
- Aura D. Herrera-MartínezAHAura D. Herrera-Martínez
- Manuel D. GaheteManuel D. Gahete
- Raúl M. LuqueRaúl M. Luque
Open Access
- 11 October 2023
- journal article
- research article
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 24 (6) , 1165-1187
Abstract
Obesity is a weight-related disorder characterized by excessive adipose tissue growth and dysfunction which leads to the onset of a systemic chronic low-grade inflammatory state. Likewise, inflammation is considered a classic cancer hallmark affecting several steps of carcinogenesis and tumor progression. In this regard, novel molecular complexes termed inflammasomes have been identified which are able to react to a wide spectrum of insults, impacting several metabolic-related disorders, but their contribution to cancer biology remains unclear. In this context, prostate cancer (PCa) has a markedly inflammatory component, and patients frequently are elderly individuals who exhibit weight-related disorders, being obesity the most prevalent condition. Therefore, inflammation, and specifically, inflammasome complexes, could be crucial players in the interplay between PCa and metabolic disorders. In this review, we will: 1) discuss the potential role of each inflammasome component (sensor, molecular adaptor, and targets) in PCa pathophysiology, placing special emphasis on IL-1β/NF-kB pathway and ROS and hypoxia influence; 2) explore the association between inflammasomes and obesity, and how these molecular complexes could act as the cornerstone between the obesity and PCa; and, 3) compile current clinical trials regarding inflammasome targeting, providing some insights about their potential use in the clinical practice.Keywords
Funding Information
- Ministerio de Ciencia, Innovación y Universidades (PID2019‐105564RB‐I00)
This publication has 237 references indexed in Scilit:
- Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE studyCancer, 2013
- Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancerOncology Letters, 2013
- Genetic variation in the toll‐like receptor 4 and prostate cancer incidence and mortalityThe Prostate, 2011
- IFI16 Acts as a Nuclear Pathogen Sensor to Induce the Inflammasome in Response to Kaposi Sarcoma-Associated Herpesvirus InfectionCell Host & Microbe, 2011
- NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for ColitisCell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Immunomodulatory IL‐18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor statusInternational Journal of Cancer, 2010
- The InflammasomesCell, 2010
- Pattern Recognition Receptors and InflammationCell, 2010
- The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE TrialEuropean Urology, 2008